This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down
by Zacks Equity Research
Intellia Therapeutics stock falls after the company announces key milestones for 2025. It plans to reduce the current workforce by 27%.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use
by Zacks Equity Research
EC expands the label of Ultragenyx's Evkeeza in the EU to treat younger patients aged 6 months to 5 years suffering from a rare cholesterol disorder.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Intellia Crashes 60% in a Year: How Should You Play the Stock?
by Ekta Bagri
NTLA stock is down significantly in 2024 as investors are not pleased with the recent data from its in vivo CRISPR-based therapies. We advise prospective investors to stay on the sidelines for now.
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study
by Zacks Equity Research
Regeneron's phase III study evaluating Eylea HD against stand-of-care Eylea treatment meets the primary endpoint of non-inferior visual gain in RVO patients.
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
by Zacks Equity Research
GILD and GSK are in the spotlight in the biotech sector with quite a few regulatory and pipeline updates.
Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases
by Zacks Equity Research
RHHBY wins approval for prefilled syringe of ophthalmology drug Vabysmo for three retinal conditions that can cause blindness.
Regeneron Down 15.5% Year to Date: How to Play the Stock?
by Ekta Bagri
REGN's lead drug, Eylea, faces a rapid decline in sales, which has impacted overall performance, even though Dupixent maintains momentum. We advise investors to wait and watch for now.
NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy
by Zacks Equity Research
The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating hereditary transthyretin (ATTR) amyloidosis with polyneuropathy.
Do Options Traders Know Something About Regeneron (REGN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Regeneron (REGN) stock based on the movements in the options market lately.
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
by Zacks Equity Research
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
Bayer Q3 Earnings Miss Estimates, Nubeqa, Kerendia Boost Sales
by Zacks Equity Research
BAYRY's third-quarter earnings get affected due to impairment losses at the Crop Science division. Sales gain from the Pharmaceutical business's strong performance.
NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Intellia's third-quarter earnings and revenues surpass estimates. The company provides updates on its pipeline candidates.
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates
by Zacks Equity Research
RARE reports encouraging third-quarter results, beating earnings and revenue estimates. Product sales increase year over year.
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
by Zacks Equity Research
ALNY's Q3 loss per share matches the Zacks Consensus Estimate and revenues miss the same due to lower collaboration revenues. The stock falls 5.3%.
HRMY vs. REGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRMY vs. REGN: Which Stock Is the Better Value Option?
Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
by Zacks Equity Research
Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.
Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 6.04% and 1.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Will a Strong Evernorth Unit Benefit Cigna in Q3 Earnings?
by Zacks Equity Research
CI's Q3 results are likely to be aided by strength in the specialty pharmacy business, partly offset by elevated medical costs resulting from higher utilization trends.
Zoetis Gears Up to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
ZTS' higher companion animal product sales are likely to have driven revenues in third-quarter 2024 in both the United States and International segments.
Top Analyst Reports for Meta Platforms, Tesla & Thermo Fisher Scientific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Tesla, Inc. (TSLA) and Thermo Fisher Scientific Inc. (TMO), as well as a micro-cap stock Where Food Comes From, Inc. (WFCF).
Regeneron to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports third-quarter 2024 results.
Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
COLL's Q3 performance is likely to have benefited from higher revenues from the sales of its pain-management drugs and the newly acquired neurology drug.